Although of interest, this study was focused on B16F10 mouse metastatic melanoma cell line, wild-type respect to either BRAF or NRAS mutations, and indicated the tumor microenvironment as key mediator of LY500307 effects, without evidence of any cell-dependent pathway activation. The gene discussed is NRAS; the disease is metastatic melanoma.